Primary and secondary outcomes
postintubation hypotension, peri-intubation adverse, cardiac arrest
SECONDARY, CARDIAC ARREST
In the etomidate group, 105 patients (80.8%) were alive at 28 days compared to 95 patients (73.1%) in the ketamine group (risk difference [RD], 7.7%; 95% confidence interval [CI], − 2.5 to 17.9%; P = 0.092). There were no significant differences between the etomidate group and the ketamine group in the proportion of patients who survived at 24 h (91.5% vs. 96.2%, respectively; RD, 4.7%; 95% CI, − 1.2 to 10.4%; P = 0.097) or survival at 7 days (87.7% vs. 87.7%; RD, 0%; 95% CI, − 7.9 to 7.9%; P = 0.574) (Table Primary and secondary outcomes.Total fluid required in the firstthree hours, median (IQR) mlUsed of a vasopressor medicationwithin 24 h after intubationPrimary and secondary outcomes.Regarding peri-intubation adverse events, cardiac arrest during intubation occurred in two patients (1.5%) in the etomidate group and two patients (1.5%) in the ketamine group (RD, 0%; 95% CI, − 2.9 to 2.9%; P = 1.0). Two patients (1.5%) in the etomidate group, but none in the ketamine group, were diagnosed with failed intubation. There was no significant difference between the study groups in the proportion of patients with postintubation hypotension (11.5% vs. 10.8%; RD, 0.7%; 95% CI, − 6.9 to 8.4%; P = 0.843); however, there were significant differences between the etomidate group and the ketamine group in the proportion of patients who needed a vasopressor within 24 h after intubation (43.9% vs. 17.7%, respectively; RD, 26.2%; 95% CI, 15.4 to 36.9%; P < 0.001) and the proportion of patients who received intravenous corticosteroids (14.6% vs. 5.4%, respectively; RD, 9.2%; 95% CI, 2.1 to 16.4%; P = 0.012) (Table 